NASDAQ$PAHC
Phibro Animal Health Corporation · Q3 2026 earnings
Q3 2026 earnings · · After market close · Investor relations
Briefing
Phibro Animal Health reported fiscal Q3 2026 net sales of $383.5M and net income of $24.0M, or $0.59 diluted EPS.
For the three months ended March 31, 2026 (fiscal Q3), Phibro posted net sales of $383.5 million, up from $347.8 million a year ago, led by Animal Health growth including the MFA acquisition. Net income was $24.0 million, or $0.59 per diluted share, versus $20.9 million and $0.51 in the prior-year quarter.
- Net sales $383.5M (+10% YoY).
- Animal Health segment $291.2M; Mineral Nutrition $73.4M.
- Net income $24.0M; diluted EPS $0.59.
- Gross profit benefited from MFA portfolio contribution.
Headline financials
Revenue & EPS history
Phibro · Revenue · Quarterly
$384M
Revenue by segment
Phibro · $231M total across 3 segments · Q1 2024
- Animal Health$161M+3.6%69.4%
- Mineral Nutrition$56M-6.0%24.2%
- Performance Products$14.8M-17.8%6.4%
Forward guidance
Demand for animal health products and integration of acquired portfolios drive outlook; FX can move reported results.
Tailwinds
- Double-digit sales growth.
- Earnings and EPS up year over year.
Headwinds
- Foreign exchange losses versus gains prior year.
- Higher SG&A from acquisition integration.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2026
-0.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
56%
29 / 52 earnings
Positive
+22.0%
Q2 2026
Best reaction
-31.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -26.1% | -37.5% | -44.6% | |
| Q2 2026 | +22.0% | +26.2% | +16.9% | |
| Q1 2026 | +4.7% | +10.2% | -4.8% | |
| Q3 2025 | +14.7% | +26.9% | +24.2% | |
| Q2 2025 | +9.9% | +16.8% | +5.7% | |
| Q1 2025 | +2.8% | +11.8% | +1.6% | |
| Q4 2024 | +1.9% | -0.3% | +4.8% | |
| Q3 2024 | +5.5% | +8.0% | +2.3% | |
| Q2 2024 | +5.9% | +12.5% | +19.1% | |
| Q1 2024 | -18.9% | -19.3% | -8.4% | |
| Q4 2023 | -5.8% | -2.0% | -13.8% | |
| Q3 2023 | -8.4% | -8.0% | -12.0% | |
| Q2 2023 | -0.9% | -1.3% | -4.7% | |
| Q1 2023 | -5.5% | -8.0% | -14.2% | |
| Q4 2022 | -4.8% | -7.4% | -24.4% | |
| Q3 2022 | -4.0% | -2.9% | -0.5% | |
| Q2 2022 | +5.7% | +13.7% | +6.0% | |
| Q1 2022 | -0.8% | -0.3% | -10.1% | |
| Q4 2021 | -5.0% | -1.0% | -10.2% | |
| Q3 2021 | +8.1% | +3.9% | +14.7% | |
| Q2 2021 | +7.3% | +7.9% | +7.5% | |
| Q1 2021 | +4.5% | +8.1% | +10.0% | |
| Q4 2020 | +0.9% | +4.6% | -13.0% | |
| Q3 2020 | -4.6% | -4.8% | +15.7% | |
| Q2 2020 | +16.9% | +14.0% | +12.5% | |
| Q1 2020 | -8.1% | -4.8% | -0.0% | |
| Q4 2019 | -31.5% | -35.0% | -32.5% | |
| Q3 2019 | -19.7% | -17.2% | -17.0% | |
| Q2 2019 | -6.4% | -10.4% | -11.8% | |
| Q1 2019 | -8.7% | -12.5% | -22.1% | |
| Q4 2018 | -3.0% | -7.0% | -15.3% | |
| Q3 2018 | +4.2% | +3.2% | +9.7% | |
| Q2 2018 | +6.8% | +4.4% | +16.0% | |
| Q1 2018 | -4.9% | -8.2% | -12.9% | |
| Q4 2017 | -5.1% | -2.4% | -0.9% | |
| Q3 2017 | +6.0% | +10.9% | +18.4% | |
| Q2 2017 | +7.0% | +12.1% | +0.2% | |
| Q1 2017 | +11.3% | +8.9% | +3.4% | |
| Q4 2016 | +15.4% | +24.9% | +28.9% | |
| Q3 2016 | -10.3% | — | — | |
| Q2 2016 | -18.2% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2015 | -5.3% | — | — | |
| Q3 2015 | +7.9% | — | — | |
| Q2 2015 | +6.5% | — | — | |
| Q1 2014 | +5.5% | — | — | |
| Q1 2015 | +7.4% | — | — | |
| Q2 2014 | +0.3% | — | — | |
| Q4 2014 | +12.6% | — | — | |
| Q4 2013 | +1.0% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro